These findings were confirmed and expanded in a subsequent study with CHC patients with metabolic dysfunction-associated steatohepatitis (MASH), describing the additional alteration of genes involved in cell cycle control (e.g., cyclin D2, CCND2), Notch signaling (e.g., mastermind like transcriptional coactivator 2, MAML2) and epithelial-mesenchymal transition (EMT) (e.g., cadherin 11, CDH11) [94]. This evidence concerns the gene MAML2 and cryohydrocytosis.